SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Friday broker round-up

Fri, 10th May 2019 13:00
(Sharecast News) - Auto Trader: Citigroup downgrades to neutral with a target price of 580p.Reckitt Benckiser Group: Barclays reiterates overweight with a target price of 7,500p.Spire Healthcare: Barclays reiterates underweight with a target price of 115p.British Land: Barclays downgrades to underweight with a target price of 500p.Ashmore Group: JP Morgan reiterates neutral with a target price of 465p.Astrazeneca: Deutsche Bank reiterates buy with a target price of 6,800p.BHP: Deutsche Bank reiterates sell with a target price of 1,650p.Mondi: Deutsche Bank reiterates buy with a target price of 2,200p.Brewin Dolphin: Canaccord reiterates sell with a target price of 237p.Beazley: Berenberg reiterates buy with a target price of 616p.Hiscox: Berenberg reiterates hold with a target price 1,581p.IAG: Berenberg reiterates buy with a target price of 780p. Astrazeneca International Airlines British Land Auto Trader Beazley Ashmore Group Spire Healthcare Hiscox Mondi BHP Group

Shares in this article

Related News

LONDON MARKET MIDDAY: FTSE pares gains as US-Iran deal lifts sentiment
9 hours ago

LONDON MARKET MIDDAY: FTSE pares gains as US-Iran deal lifts sentiment

(Alliance News) - Stock prices in London surrendered much of their early advance by midday on Monday, although remained in positive territory as inves...

Market News Endeavour Mining + 14 more shares
LONDON MARKET OPEN: European stocks rally on agreed US-Iran peace deal
12 hours ago

LONDON MARKET OPEN: European stocks rally on agreed US-Iran peace deal

(Alliance News) - Stock prices in Europe opened firmly higher on Monday after the US and Iran agreed an interim framework aimed at reopening the Strai...

Market News Antofagasta + 10 more shares
AstraZeneca's Ultomiris wins US FDA priority review in kidney disease
13 hours ago

AstraZeneca's Ultomiris wins US FDA priority review in kidney disease

(Alliance News) - AstraZeneca PLC on Monday said the US Food & Drug Administration has accepted and granted priority review to a supplemental biologic...